Stock Watch: Amarin And Esperion Cut Sales And Marketing Costs
When Sales Decline Or Launches Falter, Marketing Costs Are The First Target
Unlike big pharma, some small commercial companies cut sales and marketing costs in 2021. But with a little imagination, it could go further.
You may also be interested in...
Apart from assuming that its new drug will always be a blockbuster, the other common mistake made by biotech companies and investors is that there will invariably be a viable market for its drug. The competition will have other ideas.
An induced-infringement attack on Hikma’s skinny-label generic version of Vascepa had been cited as evidence of the potential harm that would be caused by controversial rulings in separate litigation involving GSK and Teva. However, these fears may now appear overstated after the claim against Hikma was dismissed.
When AstraZeneca closed out big pharma earnings season, its usually dominant therapeutic franchise missed analysts’ expectations. Merck’s, on the other hand, did not disappoint.